RXRX

At a glance

Recursion Pharmaceuticals Inc (RXRX) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Salt Lake City, United States and has 600 employees. The company is worth $1.92B. Revenue was $74.68M in fiscal 2025, up 26.9% from the year before. It reported a net loss of $644.76M. The share price is 44.9% below its 52-week high of $6.50. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Baillie Gifford (Baillie Gifford & Co), at $86.2M. In that quarter, 3 of them reduced the position. Over the last 30 days, company insiders sold $367K of its stock on the open market and bought none. All of those sales were scheduled in advance under 10b5-1 plans.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$1.92B

P/E

—

Forward P/E

—

P/B

2.1x

Dividend yield

0.00%

Payout

—

EPS

-$1.00

ROE

-56.58%

Profit margin

0.00%

Revenue growth

-60.10%

Beta

1.03

52-week high

$6.50

52-week low

$2.77

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• BG
  Baillie GiffordHeld

  Baillie Gifford & Co · Q2 2026
  $86.2M

  23.49M shares · 0.1% of portfolio
• TS
  Two Sigma− Reduced

  Two Sigma Investments · Q2 2026
  $12.31M

  3.35M shares · 0.0% of portfolio
• IE
  Israel Englander− Reduced

  Millennium Management · Q2 2026
  $6.73M

  1.83M shares · 0.0% of portfolio

Indicators, year by year

The last 5 closed years, each at that year’s closing price and reported numbers.

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company